sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing Few t(9;11) translocations in DNA topoisomerase II inhibitor-related leukemias have been studied in detail and the DNA damage mechanism remains controversial. We characterized the der(11) and der(9) genomic breakpoint junctions in a case of AML following etoposide and doxorubicin. Etoposide-, etoposide metabolite-and doxorubicin-induced DNA topoisomerase II cleavage was examined in normal homologues of the MLL and AF-9 breakpoint sequences using an in vitro assay. Induction of DNA topoisomerase II cleavage complexes in CEM and K562 cell lines was investigated using an in vivo complex of enzyme assay. The translocation occurred between identical 5 0 -TATTA-3 0 sequences in MLL intron 8 and AF-9 intron 5 without the gain or loss of bases. The 5 0 -TATTA-3 0 sequences were reciprocally cleaved by DNA topoisomerase II in the presence of etoposide, etoposide catechol or etoposide quinone, creating homologous 4-base 5 0 overhangs that would anneal to form both breakpoint junctions without any processing. der(11) and der(4) translocation breakpoints in a treatment-related ALL at the same site in MLL are consistent with a damage hotspot. Etoposide and both etoposide metabolites induced DNA topoisomerase II cleavage complexes in the hematopoietic cell lines. These results favor the model in which the chromosomal breakage leading to MLL translocations in DNA topoisomerase II inhibitorrelated leukemias is a consequence of DNA topoisomerase II cleavage.
Few t(9;11) translocations in DNA topoisomerase II inhibitor-related leukemias have been studied in detail and the DNA damage mechanism remains controversial. We characterized the der(11) and der(9) genomic breakpoint junctions in a case of AML following etoposide and doxorubicin. Etoposide-, etoposide metabolite-and doxorubicin-induced DNA topoisomerase II cleavage was examined in normal homologues of the MLL and AF-9 breakpoint sequences using an in vitro assay. Induction of DNA topoisomerase II cleavage complexes in CEM and K562 cell lines was investigated using an in vivo complex of enzyme assay. The translocation occurred between identical 5 0 -TATTA-3 0 sequences in MLL intron 8 and AF-9 intron 5 without the gain or loss of bases. The 5 0 -TATTA-3 0 sequences were reciprocally cleaved by DNA topoisomerase II in the presence of etoposide, etoposide catechol or etoposide quinone, creating homologous 4-base 5 0 overhangs that would anneal to form both breakpoint junctions without any processing. der(11) and der(4) translocation breakpoints in a treatment-related ALL at the same site in MLL are consistent with a damage hotspot. Etoposide and both etoposide metabolites induced DNA topoisomerase II cleavage complexes in the hematopoietic cell lines. These results favor the
Introduction
In the 1980s, the introduction of epipodophyllotoxins into clinical usage ushered in a form of treatment-related leukemia characterized by balanced translocations (Secker-Walker et al., 1985; Weh et al., 1986; Ratain et al., 1987) , which most often are translocations of the MLL gene at chromosome band 11q23 (Rowley and Olney, 2002) . The absence of PCR-detectable translocations before the start of chemotherapy (Megonigal et al., 2000; Blanco et al., 2001; Raffini et al., 2002a) and the general association of DNA topoisomerase II inhibitors, but not other cytotoxic chemotherapies, with leukemias with MLL translocations argue that DNA topoisomerase II inhibitors cause the translocations rather than selecting for translocations pre-existing in the marrow (Megonigal et al., 2000) . However, the mechanism of damage to MLL and to its partner genes remains controversial and DNA topoisomerase II and/or an apoptotic nuclease have been implicated in the damage process (Betti et al., 2001 (Betti et al., , 2003 Felix, 2001; Sim and Liu, 2001 ).
DNA topoisomerase II changes DNA topology from relaxed to supercoiled states by transiently cleaving and religating both strands of the double helix (Fortune and Osheroff, 2000) . Chemotherapeutic DNA topoisomerase II inhibitors, more accurately referred to as DNA topoisomerase II poisons, increase the concentration of enzyme-DNA covalent complexes and have the overall effect of enhancing cleavage (Fortune and Osheroff, 2000) . It has been suggested that the same DNA damage mechanism that forms the basis for their cytotoxic action may be relevant to translocations (Felix, 2001) . The genotype of CYP3A4, which converts epipodophyllotoxin into its catechol metabolite, influences the risk of treatment-related leukemias with MLL translocations . This epidemiological association was recently validated (Ben-Yehuda et al., 2002) . Epipodophyllotoxin catechol is readily oxidized to a quinone; these metabolites and reactive oxygen species produced during their redox cycling are genotoxins. Etoposide and its metabolites enhance DNA topoisomerase II cleavage at or near MLL translocation breakpoints (Lovett et al., 2001a, b) .
The t(9;11) is the most common translocation disrupting band 11q23 in treatment-related leukemia (Bloomfield et al., 2002) . The genomic sequences of both breakpoint junctions provide primary mechanistic insights into the translocation process, but both MLL genomic breakpoint junctions have been examined in few treatment-related cases (Domer et al., 1995; Megonigal et al., 1997 Megonigal et al., , 2000 Lovett et al., 2001a; Raffini et al., 2002b; Langer et al., 2003) . We characterized the genomic breakpoint junction sequences on both derivative chromosomes of a t(9;11) in the case of treatment-related AML and investigated whether the repair of DNA topoisomerase II-mediated breakage in MLL and AF-9 could have formed both breakpoint junctions. In vivo complex of enzyme (ICE) bioassays were implemented to examine the induction of DNA topoisomerase II cleavage complexes by etoposide and its metabolites in hematopoietic cell lines. The induction of DNA topoisomerase II cleavage complexes by etoposide metabolites had not been previously studied in the cellular context.
Results

Case history
Patient t-24 was diagnosed at 15 years of age with paratesticular rhabdomyosarcoma metastatic to the lungs and bone. Treatment included surgical resection of the primary tumor, one cycle of phase II window therapy with topotecan, and intensive chemotherapy as per the NCI 93-C-0125 regimen with five cycles of vincristine, doxorubicin and cyclophosphamide followed by G-CSF. Three consolidation cycles followed, each including melphalan, ifosphamide, etoposide, G-CSF and autologous peripheral hematopoietic stem cell rescue. Cumulative leukemogenic chemotherapy included 450 mg/m 2 of doxorubicin, 12 000 mg/m 2 of cyclophosphamide, 180 mg/m 2 of melphalan, 40 800 mg/m 2 of ifosphamide and 2400 mg/m 2 of etoposide. At 2 years after the initial diagnosis and 18 months after the completion of this treatment, the patient presented with thrombocytopenia and mild inguinal adenopathy. The marrow was replaced with FAB M4 AML. The G-banded karyotype in 19 metaphase cells was 46,XY,t(9;11)(p21;q23). The patient succumbed rapidly to AML despite aggressive treatment.
Fluorescence in situ hybridization analysis shows MLL translocation FISH analysis showed disruption of the MLL gene by the reciprocal t(9;11) translocation (Figure 1 ).
Genomic. cloning reveals precise interchromosomal DNA recombination
Southern blot analysis of BamHI-digested DNA prepared from the bone marrow at AML diagnosis showed 20-kb and 2.1-kb MLL bcr rearrangements (Figure 2a) . A 2.1-kb reverse panhandle PCR product indicated that the 2.1-kb rearrangement was from the der(9) chromosome ( Figure 2b ). The der(9) breakpoint in the partner DNA was position 4705, 4706, 4707, 4708, 4709 or 4710 in AF-9 intron 5 (GenBank No. AC002053). The der(9) breakpoint in MLL was position 6588, 6589, 6590, 6591, 6592 or 6593 in intron 8. The same 5 0 -TATTA-3 0 sequence and other identical short sequences were present at/near the breakpoints in both genes ( Figure 2b ). Figure 1 Metaphase FISH analysis of AML of patient t-24. FISH analysis of a metaphase cell with a probe for MLL (red) showed the disruption of MLL by the t(9;11) observed in the G-banded karyotype DNA topoisomerase II cleavage and secondary AML RJ Whitmarsh et al PCR with MLL-and AF-9-specific primers amplified a 452-bp product containing the der(11) genomic breakpoint junction predicted by the der(9) sequence. The MLL breakpoint on the der(11) chromosome was position 6587, 6588, 6589, 6590, 6591 or 6592 in intron 8; the AF-9 breakpoint on the der(11) chromosome was position 4706, 4707, 4708, 4709, 4710 or 4711 in intron 5 (Figure 2c ). The der(11) breakpoints in MLL and AF-9 involved the exact same 5 0 -TATTA-3 0 sequences as the der(9) breakpoints in both genes. It has been suggested that the relevant DNA double-strand break-repair mechanism in MLL translocations is nonhomologous end-joining (NHEJ) (Domer et al., 1995; Felix et al., 1997 Felix et al., , 1999 Super et al., 1997; Megonigal et al., 1998 Megonigal et al., , 2000 Gillert et al., 1999; Lovett et al., 2001a; Raffini et al., 2002b) , but the 5 0 -TATTA-3 0 sequences in MLL and AF-9 (Figure 2b , c) suggested more bases of homology than have been observed at other MLL genomic breakpoint junctions (Domer et al., 1995; Felix et al., 1997 Felix et al., , 1999 Super et al., 1997; Megonigal et al., 1998 Megonigal et al., , 2000 Gillert et al., 1999; Lovett et al., 2001a; Raffini et al., 2002b) . Comparison of the der(11) and the der(9) sequences showed that the translocation had occurred without the gain or loss of bases.
Reciprocal DNA topoisomerase II cleavage events at 5 0 -TATTA-3 0 sequences in MLL and AF-9 create staggered DNA double-strand breaks with homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions without any processing
The translocation breakpoints in MLL and AF-9 coincided with functional drug-induced DNA topoisomerase II cleavage sites. Since prior therapy in patient t-24 included etoposide and doxorubicin, in vitro cleavage of substrate DNAs containing the normal homologues of the MLL and AF-9 genomic breakpoints was analysed after incubation with human DNA topoisomerase IIa in the absence of drug and in the presence of etoposide, its catechol or quinone metabolites, or doxorubicin. In the absence of drug, little cleavage was detectable in either substrate (Figure 3a , b). Multiple DNA topoisomerase II cleavage sites were induced in both substrates by etoposide and its metabolites, but fewer sites were induced by doxorubicin ( Figure 3a ,b, no heat ( þ )topo). In the substrate comprising positions 6513 to 6778 in MLL intron 8 (Figure 3a) , the sequence encompassing the der(11) and der(9) breakpoint was studied in detail. If the coordinate indicates the base at the 5 0 side of the cleavage site (9) genomic breakpoint junction in recombination-PCR generated subclones from reverse panhandle PCR. The reverse panhandle PCR product was consistent with 2.1 kb MLL bcr rearrangement. One subclone was sequenced in entirety; the breakpoint junction was verified in seven other subclones. In reverse panhandle PCR, nested primer 3 from MLL exon 11/intron 10 anneals to both ends of the template. The 35 bp of 5 0 sequence extend from MLL primer 3 through ligated oligonucleotide. The 442-447 bp of 5 0 sequence are AF-9. The 3 0 1706-1711 bp include MLL bcr sequence through MLL primer 3. Arrowheads show AF-9 and MLL breakpoint positions; identical 5 0 -TATTA-3 0 sequences in AF-9 intron 5 and MLL intron 8 precluded precise breakpoint assignments (bottom, underlined). Other short homologies are underlined (bottom). Repetitive sequences are shown (middle). The der(9) breakpoint junction involving the 5 0 -TATTA-3 0 sequence was confirmed by sequencing the 390-bp products of 2 independent PCRs. (c) Summary of der(11) genomic breakpoint junction in products of conventional PCR. Gene-specific primers were designed from the der(9) sequence shown in (b) to amplify the predicted der(11) genomic breakpoint junction. The expected 452-bp product was obtained and the sequence of the der(11) genomic breakpoint junction was determined in the products from 4 PCRs. The 5 0 sequence is MLL intron 8. The 3 0 sequence is AF-9 intron 5. The same 5 0 -TATTA-3 0 sequence observed at the der(9) genomic breakpoint junction occurred at the breakpoint junction of the der(11) chromosome, indicating a precise translocation at the sequence level (i.e. a translocation without the gain or loss of bases). Arrowheads show MLL and AF-9 breakpoint positions; 5 0 -TATTA-3 0 sequence in both genes precluded precise breakpoint assignments (underlined). Other short sequence homologies are underlined. These genomic breakpoint junctions suggest more bases of homology than MLL genomic breakpoint junctions in other de novo or treatment-related leukemias where nonhomologous end-joining has been implicated (Felix et al., , 1999 Table 1 shows the intensities of cleavage induced by etoposide, etoposide catechol, etoposide quinone and doxorubicin at MLL bcr positions 6587, 6588 and 6589 relative to the reference site, and rankings of these sites compared to other sites induced by the respective agent in this substrate. Etoposide-induced cleavage at position 6588 and etoposide catechol-and quinone-induced cleavage at positions 6587, 6588 and 6589 remained detectable after heating for 10 min at 751C, indicating stability of the relevant enzyme-DNA covalent complexes ( Figure 3a , heat ( þ )topo).
The sequence encompassing the der(11) and der(9) AF-9 breakpoint was studied in detail in the substrate spanning AF-9 intron 5 positions 4612 to 4905 ( Figure 3b Table 2 shows the intensities of cleavage induced by these agents at AF-9 positions 4705 and 4706 relative to the reference site and the ranking of these sites compared to other sites induced by each respective agent in this substrate. The DNA topoisomerase II covalent complexes formed at positions 4705 and 4706 in the presence of etoposide and both etoposide metabolites were heat stable and doxorubicin induced heat-stable cleavage at position 4706 ( Figure 3b , heat ( þ )topo).
Since the translocation occurred without the gain or loss of bases (i.e. was precise at the sequence level), we explored how and which of the functional DNA topoisomerase II cleavage sites in MLL and AF-9 could be resolved to form the observed breakpoint junctions. It has been shown before that DNA topoisomerase II introduces 4-base staggered nicks in duplex DNA and creates 4-base 5 0 overhangs by introducing coordinated nicks on opposite strands of the double helix (Burden and Osheroff, 1998; Fortune and Osheroff, 2000) . Each enzyme subunit forms a covalent phosphodiester bond between its active site tyrosine residue and the 5 0 -phosphate terminus created in the scission (Burden and Osheroff, 1998; Fortune and Osheroff, 2000) . In the model shown in Figure 4 , the 4-base 5 0 overhangs created by DNA topoisomerase II cleavage at MLL position 6587 and AF-9 position 4705 are perfectly homologous and preserved completely. Repair of the overhangs occurs without any processing. Figure 4 details the simplest model for the creation of both breakpoint junctions; different models derived from the other proximal cleavage sites require added processing (not shown).
MLL translocation breakpoints in treatment-related ALL of patient t-120 occur at DNA topoisomerase II cleavage site in the same genomic region
The der(11) and der(4) genomic breakpoint junctions of a t(4;11) in the treatment-related ALL of patient t-120 have been described (Raffini et al., 2002b) . The MLL der(11) genomic breakpoint (position 6588 or 6589) and the MLL der(4) genomic breakpoint (position 6594, 6595 or 6596) were in the exact same region of the bcr as the breakpoints in the case of patient t-24. The der(11) breakpoint was at the functional DNA topoisomerase II cleavage sites at MLL bcr positions 6588 and 6589 (Figure 3a) . Exonucleolytic nibbling of a few bases from the 3 0 side of these cleavage sites would generate the MLL breakpoint site (position 6594, 6595 or 6596) on the der(4).
Etoposide and etoposide metabolites induce the formation of DNA topoisomerase II cleavage complexes in human hematopoietic cell lines ICE bioassays demonstrated significant induction of DNA topoisomerase II cleavage complexes in CEM cells by 20 mM etoposide or its catechol or quinone metabolites (Figure 5a ). The cleavage complexes induced by etoposide catechol were comparable in amount to the parent drug. The induction of DNA cleavage complexes was observed in K562 cells treated with 20 mM etoposide or etoposide quinone (Figure 5b) . Consistent with the presence of DNA bound to the enzyme, the DNA topoisomerase IIa protein ran higher than its known molecular weight of 170 kDa. However, no induction of DNA topoisomerase II cleavage complexes was detected in either CEM or K562 cells after treatment with doxorubicin at the same concentration. Percentages of viable CEM and K562 cells after etoposide, etoposide catechol, etoposide quinone or doxorubicin exposure for 2 h at 20 mM concentration were similar to untreated cells (Table 3) . 
Discussion
The mechanism of damage to MLL and its many partner genes from chemotherapeutic DNA topoisomerase II inhibitors that results in translocations remains controversial. This work provides mounting evidence that DNA topoisomerase II can mediate this damage. Patient t-24 had received prior sarcoma therapy with two different DNA topoisomerase II inhibitors. Reverse panhandle PCR (Raffini et al., 2002b) enabled cloning of the der(9) genomic breakpoint junction of the t(9;11) and PCR with gene-specific primers amplified the predicted der(11) genomic breakpoint junction. Approaches for cloning both genomic breakpoint junctions are prerequisite to localizing the genomic regions where DNA damage has occurred and has been resolved to form translocations. 2001a; Raffini et al., 2002b; Langer et al., 2003) . Nonetheless, patterns are emerging that are relevant to the damage and its resolution: (1) the interchromosomal DNA recombination occurs with overall gains or losses of either no or, most often, relatively few bases in the formation of both breakpoint junctions, suggesting minimal processing (i.e. the interchromosomal DNA recombination is precise or near-precise) (Domer et al., 1995; Megonigal et al., 1997 Megonigal et al., , 2000 Lovett et al., 2001a; Raffini et al., 2002b; Langer et al., 2003) ; (2) the MLL genomic breakpoint sites are distributed heterogeneously in introns in the bcr with emerging breakpoint hotspots (Domer et al., 1995; Megonigal et al., 1997 Megonigal et al., , 2000 Sobulo et al., 1997; Atlas et al., 1998; Daheron et al., 2001; Lovett et al., 2001a; Raffini et al., 2002b; Langer et al., 2003) ; (3) short sequence homologies between MLL and partner genes are characteristic of the breakpoint junctions (Domer et al., 1995; Megonigal et al., 1997 Megonigal et al., , 2000 Sobulo et al., 1997; Atlas et al., 1998; Daheron et al., 2001; Lovett et al., 2001a; Raffini et al., 2002b; Langer et al., 2003) . Microhomologies at and near the breakpoint junctions in de novo and treatment-related MLL-rearranged leukemias are consistent with the DNA double-strand break-repair mechanism of NHEJ (Domer et al., 1995; Felix et al., 1997 Felix et al., , 1999 ; Super et al., 1997; Megonigal 0 sense-strand overhang (positions 4706-4709) of AF-9 are perfectly homologous and anneal without any processing to create the der(11). The der(11) forms by fusion of position 6587 on the MLL sense strand to position 4706 on the AF-9 sense strand. Conversely, the entire 4-base 5 0 antisense-strand overhang (positions 4706-4709) of AF-9 and the entire 4-base 5 0 sense-strand overhang (positions 6588-6591) of MLL are perfectly homologous and anneal without any processing to create the der(9). The der(9) forms by fusion of position 4705 on the AF-9 sense strand to position 6588 on the MLL sense strand Figure 5 Modified ICE assay. CEM (a) and K562 (b) cells were treated for 2 h with the indicated drugs at 20 mM final concentration. Untreated CEM and K562 cells were controls. Total DNA including any protein-bound DNA was isolated using a CsCl cushion and 5 mg per lane were loaded on a 4-12% Bis-Tris gradient gel. Western blot was performed using an anti-human DNA topoisomerase IIa antibody to detect DNA topoisomerase II-bound DNA , 1998 Gillert et al., 1999; Lovett et al., 2001a; Raffini et al., 2002b) . However, the treatmentrelated leukemia of patient t-24 is novel inasmuch as precise interchromosomal DNA recombination occurred without the gain or loss of bases and without additional processing. Most DNA double-strand breaks from mutagenic agents cannot be directly ligated and some limited processing, including small deletions and/or DNA polymerization is required before NHEJ occurs (Liang et al., 1998; Jackson, 2002) . This is consistent with several small deletions (Megonigal et al., 2000; Raffini et al., 2002b ) and a templated singlebase insertion (Lovett et al., 2001a) that we reported at various breakpoint junctions in treatment-related leukemias shown in Figure 6 (c.f. cases t-39, t-120 and t-33). The rearrangement between identical 5 0 -TATTA-3 0 sequences in MLL intron 8 and AF-9 intron 5 without the gain or loss of any bases in the treatment-related leukemia of patient t-24 is compelling evidence that the sites of damage and the translocation breakpoints in MLL and AF-9 were the same. Although NHEJ repair events generally ensue after small deletions or insertions at the break site (Liang et al., 1998) , the formation of breakpoint junctions in the treatment-related leukemias with minimal or no processing indicates relationships between the damage regions and observed translocation breakpoints.
In vitro assays demonstrating DNA topoisomerase II cleavage sites at the 5 0 -TATTA-3 0 sequences in MLL and AF-9 provide functional evidence that the repair of DNA topoisomerase II-mediated breakage in MLL and AF-9 could have formed both breakpoint junctions. The formation of the observed breakpoint junctions by the annealing of perfectly homologous 4-base 5 0 overhangs of cleavage sites also may suggest the alternative repair mechanism of DNA topoisomerase II subunit exchange, whereby DNA strands undergo recombination via the exchange of enzyme subunits (Bae et al., 1988; Charron and Hancock, 1991; Zhou et al., 1997) . Previously, the DNA topoisomerase II subunit exchange mechanism followed by repair of mismatches in the cohesive ends was proposed for the precise interchromosomal translocation between hotspots for DNA topoisomerase II cleavage sites in the aprt locus and an unrelated sequence in amsacrine-treated Chinese hamster ovary cells (Zhou et al., 1997) . However, this is the first precise drug-induced recombination that has been reported in a patient and, unlike in the experimental model (Zhou et al., 1997) , no further processing was needed. Nevertheless, induction by the relevant agents of functional DNA topoisomerase II cleavage sites in vitro, repair of which could lead to both genomic breakpoint junctions, supports disruption of the DNA topoisomerase II Figure 6 MLL genomic breakpoint sites in the bcr in treatment-related leukemias where only the der(11) (fine arrows, top), only the der(other) (fine arrows, bottom) or both genomic breakpoint junctions (bold arrows, top and bottom) have been cloned (Domer et al., 1995; Megonigal et al., 1997 Megonigal et al., , 2000a Sobulo et al., 1997; Atlas et al., 1998; Daheron et al., 2001; Lovett et al., 2001a; Raffini et al., 2002b) cleavage-religation equilibrium as the damage mechanism in this translocation.
The more precise MLL recombinations in the treatment-related leukemias and heterogeneity in breakpoint distribution (Figure 6 ) together incriminate a damaging event that occurs at many different sites. DNA topoisomerase II-mediated damage at multiple different sites in these and prior DNA topoisomerase II cleavage assays (Felix et al., 1995; Lovett et al., 2001a, b) is consistent with the heterogeneity in translocation breakpoint distribution, although cleavage sites in the cellular chromatin context should be more restricted (Capranico et al., 1990a) . The similar MLL breakpoint sites in cases t-120 (Raffini et al., 2002b) and t-24 may indicate a preferred damage site in the heterogeneous background (Fortune and Osheroff, 2000) , and may be consistent with the damage hotspot previously suggested by the biased MLL translocation breakpoint distribution 3 0 in the bcr from Southern blot analysis of treatment-related leukemias in adults (Broeker et al., 1996) . We also reported on the treatment-related leukemia of patient t-13 with a breakpoint at MLL intron 6 position 1493 Lovett et al., 2001b) near another published breakpoint (Figure 6 ), possibly suggesting a more 5 0 damage hotspot. While this paper was in review, Langer et al. (2003) described both genomic breakpoint junctions of t(9;11) translocations in four cases of treatment-related AML, and the der(11) breakpoint junction in another case. The genomic cloning in each of these five cases indicates involvement of the exact same genomic region of the MLL bcr as in the AML of patient t-24 ( Figure 6 ). In cases P8 and P10, there were 1-4-bp and 10-bp deletions with respect to the normal sequence of the MLL bcr, and in cases P4 and P6 there were 2-5-bp and 6-bp duplications (Langer et al., 2003) . Therefore, the additional cases further indicate that the breakpoint site in MLL in the AML of patient t-24 is a DNA damage hotspot; however, precise recombination without the gain or loss of any bases still appears uncommon. Although there were two different 5 0 -TATTA-3 0 motifs proximal to the AF-9 genomic breakpoints in case P10, none of the AF-9 breakpoints in the cases reported on by Langer (Langer et al., 2003) were in the same genomic region of AF-9 as in the case of patient t-24.
The DNA topoisomerase II cleavage assays described herein also suggest a potential role for DNA topoisomerase II cleavage in the five treatment-related leukemias that Langer recently described (Langer et al., 2003) , the translocation breakpoints in which are shown in Figure 6 . In four of the five cases there was exposure to the DNA topoisomerase II inhibitor doxorubicin (Patients P4, P6, P9, P10). There was additional daunorubicin exposure in patients P6 and P9, and exposure to the DNA topoisomerase I/II inhibitor dactinomycin in patient P10. In case P8, the prior genotoxic chemotherapeutic agents were not DNA topoisomerase II inhibitors (Langer et al., 2003) . The cleavage assay shown in Figure 3a indicates that doxorubicin induced functional, although weaker DNA topoisomerase II cleavage, at MLL bcr position 6588 and that there were several enzyme-only cleavage sites proximal to these translocation breakpoints. It is possible that enzyme-only DNA topoisomerase cleavage may have been important in case P8 and possibly other cases. DNA topoisomerase II catalyses the relaxation of supercoiled DNA for many important cellular process, including replication, transcription, chromosome condensation and mitosis (Wang, 1996) . Cytotoxic chemotherapy forces bone marrow repopulation and recovery, which creates a situation where native DNA topoisomerase II cleavage should be active since DNA topoisomerase IIa expression is highest in proliferating tissues (Isaacs et al., 1998) . Therefore, several cleavage sites shown in Figure 3a may have been of relevance in the cases reported on by Langer.
In de novo MLL-rearranged leukemias, there is also heterogeneity in breakpoint distribution (Negrini et al., 1993; Felix et al., 1997 Felix et al., , 1999 Super et al., 1997; Megonigal et al., 1998; Reichel et al., 2001; Raffini et al., 2002b; Slater et al., 2002) . In an analysis of de novo ALLs with t(4;11), two breakpoint clusters were suggested in the MLL bcr, cluster I of breakpoints in ALLs in children and adults corresponding to intron 7, and cluster II of breakpoints in ALLs in infants corresponding to the region of 3 0 intron 8 (Reichel et al., 2001) , the latter of which coincides with the breakpoint locations in cases t-24, t-120 and the treatment-related leukemias recently described by Langer (Langer et al., 2003) . (N.B. Alternative designations for MLL bcr exons/introns in the cited reference (Reichel et al., 2001 ) where exons 5 through 11 were called exons 8 through 14, respectively.) In leukemia in infants, classical epidemiological studies suggest that maternal exposure to dietary DNA topoisomerase II inhibitors may increase the risk (Ross et al., 1996; Ross, 2003) . However, de novo MLL-rearranged leukemias often contain duplications or deletions of several hundred bases or inverted sequences (Super et al., 1997; Felix et al., 1999; Reichel et al., 2001; Raffini et al., 2002b) , which differs from treatment-related cases. DNA topoisomerase II introduces single-stranded nicks in duplex DNA as kinetic intermediates of doublestranded breaks (Muller et al., 1988; Andersen et al., 1989; Osheroff, 1989; Zechiedrich et al., 1989; Lee and Hsieh, 1992) . It was also recently shown that double occupancy by etoposide at either scissile bond between the DNA and DNA topoisomerase II subunit is needed for a double-stranded break; this observation may further explain how certain DNA topoisomerase II inhibitors can induce single-stranded nicks (Bromberg et al., 2003) . In the infant cases, the epidemiology and breakpoint junction sequences may suggest a mechanism in which two type II DNA topoisomerases introduce separate single-stranded nicks in duplex DNA that are staggered by up to several hundred bases, and template-directed polymerization of the single-stranded overhangs between the staggered nicks generates duplications. The large deleted regions observed in other infant cases are consistent with multiple sites of breakage or, alternatively, more extensive processing (Super et al., 1997; Gillert et al., 1999; Raffini et al., 2002b; Slater et al., 2002) .
The specific homologous 5 0 -TATTA-3 0 sequence identified at the MLL breakpoint 3 0 in intron 8 in the case of patient t-24 is not a previously recognized DNA topoisomerase II target. An alternative mechanism has been proposed, whereby cleavage by an apoptotic nuclease within the MLL bcr is responsible for the damage (Betti et al., 2001 (Betti et al., , 2003 Sim and Liu, 2001) . After exposure of hematopoietic cell lines to chemotherapeutic DNA topoisomerase II inhibitors, Southern blot experiments detect a breakage site 3 0 in the MLL bcr (Aplan et al., 1996; Stanulla et al., 1997; Strissel et al., 1998; Strick et al., 2000; Sim and Liu, 2001 ). This site is induced by several other general cytotoxic agents that cause apoptosis (Stanulla et al., 1997; Sim and Liu, 2001) . However, in several treatment-related leukemias shown in Figure 6 , the MLL der(11) and or the der(other) genomic breakpoints are more 5 0 in the bcr. The breakage site 3 0 in the MLL bcr would not account for translocations in which both the MLL der(11) and der(other) genomic breakpoints are more 5 0 in the bcr. It is possible that the MLL bcr is susceptible to site-specific cleavage by DNA topoisomerase II and an apoptotic nuclease as others have suggested (Sim and Liu, 2001) , since DNA topoisomerase II cleavage both initiates apoptosis (Kaufmann, 1998) and is associated with recombination (Bae et al., 1988; Wang et al., 1990; Charron and Hancock, 1991; Pommier and Bertrand, 1993; Zhou et al., 1997; Sim and Liu, 2001) .
The recently validated association of CYP3A4-W genotype with an increased risk of treatment-related leukemia with MLL translocations Ben-Yehuda et al., 2002) , the conversion of etoposide to genotoxic metabolites by CYP3A, prior demonstration that etoposide catechol and etoposide quinone induce DNA topoisomerase II cleavage (Lovett et al., 2001a, b) and the specific drug exposures formed the basis to investigate the potential role of etoposide metabolites in the genesis of the t(9;11) in the AML of patient t-24. The simplest model for the formation of both breakpoint junctions was derived from functional DNA topoisomerase II cleavage sites at MLL intron 8 position 6587 and AF-9 intron 5 position 4705. Doxorubicin did not induce detectable cleavage at either MLL bcr position 6587 or AF-9 position 4705, possibly suggesting that exposure to etoposide and/or its metabolites, but not doxorubicin, was relevant to the leukemia of this patient.
We modified the ICE bioassay to determine whether etoposide metabolites induce DNA-DNA topoisomerase II covalent complexes in the chromatin context of hematopoietic cell lines. The assay entails trapping the DNA covalently bound to DNA topoisomerase II by phosphotyrosine linkage using protein denaturants, and immunodetection (Subramanian et al., 1995 (Subramanian et al., , 2001 Pourquier et al., 2000; Byl et al., 2001) . Isolation of the protein-bound DNA using a CsCl cushion streamlines the methodology compared to prior versions, and the change from slot blot analysis to Western blot analysis enables size-separation of the DNA-protein complexes. Etoposide induced significant DNA topoisomerase II cleavage complexes in CEM and K562 cells as expected from existing data (Byl et al., 2001) . Induction of DNA topoisomerase II cleavage complexes was also observed when CEM and K562 cells were treated with etoposide metabolites, which had not been previously studied in this assay. Although the ICE assay does not address the enzyme-DNA interaction at the sequence level, detection of DNA topoisomerase II cleavage complexes in hematopoietic cell lines corroborates the induction of DNA topoisomerase II cleavage complexes by etoposide catechol and etoposide quinone that was observed in vitro. Doxorubicin is an intercalative DNA topoisomerase II inhibitor that induces DNA topoisomerase II cleavage with different sequence site-selectivity (Capranico et al., 1990b) . Doxorubicin is also associated with leukemia as a treatment complication, albeit less often (Sandoval et al., 1993) . Doxorubicin induced cleavage at fewer sites in the in vitro assay, and no increased formation of DNA topoisomerase II cleavage complexes was appreciable within the limits of sensitivity of the ICE assay when CEM and K562 cells were exposed to doxorubicin.
The treatment-related AML with t(9;11) in this report is the first case where functional DNA topoisomerase II cleavage sites induced by etoposide and its metabolites formed reciprocal overhangs for interchromosomal DNA recombination between MLL and its partner gene without any processing or repair of mismatched bases. That etoposide metabolites disrupt the DNA-DNA topoisomerase II cleavagereligation equilibrium in hematopoietic cell lines also is new information. Enhanced DNA topoisomerase II cleavage is the accepted mechanism of cytotoxicity of epipodophyllotoxin anticancer drugs (Fortune and Osheroff, 2000) . The gravity and increasing incidence of DNA topoisomerase II inhibitor-related leukemias mandates a better understanding of the relationship between the mechanism of cytotoxicity and the mechanism whereby these drugs cause translocations. These results favor the model in which DNA topoisomerase II mediates chromosomal breakage that results in translocations, particular DNA topoi somerase II inhibitors contribute to the breakage in specific cases, and translocations form when this breakage is repaired.
Materials and methods
The IRB at The Children's Hospital of Philadelphia approved this research.
Fluorescence in situ hybridization analysis (FISH)
A DNA probe for MLL (Ventana Medical Systems, Tuscon, AZ, USA) was hybridized to slides prepared for cytogenetic analysis at the time of AML diagnosis. FISH was performed according to standard procedures. Images were acquired using Leica Q-FISH software (Leica Imaging Systems, Cambridge, UK).
Southern blot analysis
The MLL bcr was examined in BamHI-digested DNA using the B859 fragment of ALL-1 cDNA (Gu et al., 1992) .
PCR analysis of translocation breakpoint junctions
Reverse panhandle PCR analysis of the der(9) genomic breakpoint junction was performed as described (Raffini et al., 2002b) . The reaction products were subcloned by recombination PCR (Raffini et al., 2002b) and sequenced. Forward and reverse primers 5 0 -GGGTCATTTGAATAG-CAGCAG-3 0 from positions 4559 to 4579 in AF-9 intron 5 (GenBank No. AC002053) and 5 0 -AAAACTTGTG-GAAGGGCTCA-3 0 from positions 6811 to 6830 in exon 9 in the MLL bcr (GenBank No. U04737) were used in conventional PCRs to confirm the der(9) genomic breakpoint junction. The AF-9 sequence in clone AC002053 is the reverse complement of the AF-9 genomic sequence; therefore, the reverse complement of AC002053 is used for reference to positions. Forward and reverse primers 5 0 -TGGAAAGGA-CAAACCAGACC-3 0 from positions 6403 to 6422 in intron 8 in the MLL bcr and 5 0 -AGATCACATACCCCACCCCT-3 0 from positions 4972 to 4953 in AF-9 intron 5, respectively, were used in conventional PCRs to isolate the der(11) genomic breakpoint junction.
DNA topoisomerase II in vitro cleavage assays
DNA fragments containing the normal homologues of the MLL and AF-9 genomic breakpoints in the AML of patient t-24 were subcloned into the BamHI and EcoRI sites of pBluescript II SK (Stratagene; La Jolla, CA, USA). Singly 5 0 end-labeled, double-stranded DNA substrates were prepared from these plasmids exactly as described (Lovett et al., 2001a) . A total of 25 ng of substrate DNA was incubated with human DNA topoisomerase IIa, ATP and MgCl 2 either in the absence of drug or in the presence of etoposide, etoposide catechol, etoposide quinone or doxorubicin at 20 mM final concentration as per the same reaction conditions used for other cleavage assays (Lovett et al., 2001a) . Covalent complexes were then irreversibly trapped by adding SDS, without or following incubation for 10 min at 751C, the latter to evaluate heat stability (Bromberg and Osheroff, 2001) . Cleavage products were deproteinized and electrophoresed in a denaturing polyacrylamide gel in parallel with a dideoxy sequencing ladder to map the sites of cleavage (Lovett et al., 2001a) .
Cell lines
The CCRF-CEM cell line originally was derived from the peripheral blood lymphoblasts of a patient with T-cell ALL (Uzman et al., 1966) . CEM cells were grown in RPMI-1640 medium (Bio-Whittaker; Walkersville, MD, USA) with 10% fetal bovine serum that was heat-inactivated at 701C (HyClone; Logan, UT, USA) supplemented with 10 mM HEPES and 1 mM sodium pyruvate. The K562 CML-derived cell line (Lozzio and Lozzio, 1979) was grown in RPMI-1640 medium (Bio-Whittaker, Walkersville, MD, USA) with 10% heatinactivated fetal bovine serum (HyClone, Logan, UT, USA). Stock cultures were maintained at 371C in a humidified 5% CO 2 incubator. Both cell lines were grown in suspension and maintained at 2-3 Â 10 5 viable cells/ml.
Modified ICE bioassay
The ICE bioassay (Subramanian et al., 1995 (Subramanian et al., , 2001 Pourquier et al., 2000; Byl et al., 2001 ) was modified to examine the induction of DNA-DNA topoisomerase II covalent complexes in CEM and K562 cell lines. Cells (4 Â 10 6 ) were incubated without drug or with 20 mM final concentration of etoposide, etoposide catechol, etoposide quinone or doxorubicin at 371C in 2 ml of medium for 2 h in a T25 flask. Percentages of viable cells were then assessed by trypan blue exclusion. Treated and untreated cells were pelleted by centrifugation at 1200 r.p.m. Â 10 min and lysed in 3.5 ml of nuclear lysis buffer containing 50 mM Tris pH 7.5, 0.5 M NaCl, 1% NP-40, 1% DOC, 0.1% SDS, 2 mM EDTA and complete protease inhibitors. The lysates were flash-frozen in liquid nitrogen and thawed at 371C before passage through a 25 G needle to shear the DNA. After centrifugation at 14 000 r.p.m. for 15 min, the supernatants were layered onto 1.5 ml CsCl (1.5 mg/ml) cushions and spun in an NVT90 rotor (Beckman; Palo Alto, CA, USA) Â 6 h at 80 000 r.p.m. in an ultracentrifuge to obtain a pellet containing the total genomic DNA and any protein-bound DNA according to the In vivo Link Kit protocol (Topogen, Inc.; Columbus, OH, USA) (Zinkevich and Beech, 2000) . The pellet was dissolved in 250 ml of 10 mM Tris-HCl (pH 8.0) 1 mM EDTA buffer. The DNA was quantified by measuring the OD 260 and 0.05 mg of DNA was visualized on an agarose gel. Five mg of DNA was analysed on a Western blot with a Western Breeze kit according to the protocol of the manufacturer (Invitrogen, Carlsbad, CA, USA). DNA topoisomerase II-bound DNA was detected with a mouse anti-human DNA topoisomerase IIa antibody (DAKO, Carpinteria, CA, USA) used at 1 mg/ml in blocking solution.
